Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer

Sponsor
Sun Yat-sen University
Study ID
NCT04539600
Phase
PHASE2
Status
Unknown

Conditions

  • Hypopharyngeal Cancer
  • Immunotherapy
  • Induction Chemotherapy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.

Study Details

The study is a single center phase II trial. The purpose is to investigate both the efficacy and safety of chemotherapy combined with anti-PD-1 antibody Followed by chemoradiotherapy in locoregionally advanced hypopharyngeal cancer.

Key Dates

Start date
Nov 1, 2020
Status verified
Aug 2021
Primary completion
Jul 31, 2022
Completion
Dec 12, 2022

Study Design

Enrollment
23 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: induction chemotherapy + anti-PD-1 antibody
    Camrelizumab (200 mg, Q3w, 2 cycles in total) combined with induction chemotherapy (taxane-containing regimen, Q3w, 2 cycles in total) followed by concurrent radiotherapy and chemotherapy.

Primary Outcome Measure

Progression-free Survival, PFS [ Time Frame: 1 year ]

Central Contacts

Related Studies